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COMPARATIVE PERFORMANCES OF SEROLOGIC AND MOLECULAR ASSAYS,
AND DETECTION OF HTLV-2b SUBTYPE
Helena Kaminami MORIMOTO(1), Arilson Akira MORIMOTO(2), Edna Maria Vissoci REICHE(1), Luiz Toshio UEDA(3), Tiemi MATSUO(4),
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SUMMARY
The current diagnosis of human T-lymphotropic virus type-2 (HTLV-2) infection is based on the search of specific antibodies;
nevertheless, several studies conducted in Brazil pointed deficiencies of the commercially available kits in detecting HTLV-2,
mostly in HIV/AIDS patients. This study searched for the presence of HTLV-1 and -2 in 758 HIV/AIDS patients from Londrina,
Paraná, Brazil. Serum samples were screened for HTLV-1/2 antibodies using two EIA kits (Vironostika and Murex), and confirmed
by WB (HTLV Blot 2.4, Genelabs). The results obtained by EIA disclosed 49 (6.5%) reactive sera: 43 positive by both EIA kits,
and six with discordant results. WB confirmed HTLV-1 infection in seven samples (0.9%) and HTLV-2 in 21 sera (2.8%). Negative
and indeterminate results were detected in four (0.5%) and 16 (2.1%) sera, respectively. Blood from 47 out of 49 HTLV seroreactive
patients were collected and analyzed for the presence of env, LTR and tax genomic segments of HTLVs by PCR. PCR confirmed
six cases of HTLV-1 and 37 cases of HTLV-2 infection (14 out of 16 that were found to be WB indeterminate). Restriction analysis
of the env PCR products of HTLV-2 disclosed 36 isolates of HTLV-2a/c subtype, and one of HTLV-2b subtype. These results
emphasize the need of improving serologic tests for detecting truly HTLV-2 infected patients from Brazil, and confirm the presence
of HTLV-2b subtype in the South of this country.
KEYWORDS: Human T-lymphotropic virus type 2 (HTLV-2); HIV/HTLV-2 coinfection; Diagnosis; Serology; PCR; HTLV-2
subtype.
INTRODUCTION
Human T-lymphotropic virus type 2 (HTLV-2) is a human retrovirus
which is endemic in Amerindians from the Amazon region of Brazil,
as well is epidemic among HIV/AIDS patients living in urban areas of
this country28.
A recent molecular subtype of HTLV-2, named HTLV-2c, was
recognized among endemic and epidemic populations from
Brazil13,15,16,18. The HTLV-2c is phylogenetically related to HTLV-2a,
but possess an extended Tax protein, similar to HTLV-2b8,15,17. This
diversity could account for the designation of HTLV-2c, which by some
authors was previously considered as a molecular variant of HTLV-
2a1,12,19,30,32.
In spite of the proximity of Brazil to other Latin America countries
where HTLV-2b is endemic28, only recently this subtype was reported
among urban population in Porto Alegre, South of Brazil27.
The routes of HTLV-2 transmission/acquisition differ from endemic
and epidemic populations: breastfeeding and sexual contact has been
reported as the major routes of transmission in endemic populations,
while parenteral transmission by intravenous drug use (IDU) or sexual
contact with IDU, are responsible for epidemic transmission of HTLV-
229.
Unfortunately, for Brazilian population, commercially available
serologic kits lack in confirming HTLV-2 infection, especially in HIV/
AIDS coinfected patients6,9. Indeed, although the controversial role of
HTLV-2 in the pathogenesis of several diseases, an association of
neurological syndromes, pneumonia, bronchitis and arthritis, have been
documented in HTLV-2-infected patients, as well as cutaneous
lymphoma in few cases of HIV/HTLV-2 co-infected patients3-4,21,28.
Paradoxically, antiretroviral therapy increases HTLV-2 proviral load,
and may alter the course of HIV disease22,25. Thus, it is important to
know the real status of HTLV-2 in HIV/AIDS patients in order to
properly attend these individuals.
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The aim of the present study was to detect the real prevalence of
HTLV-2 infection in HIV/AIDS patients from the South of Brazil using
serologic and molecular assays, and by restriction analysis of one
segment of the env gene of HTLV-2, confirm HTLV-2b subtype in this
geographic area.
MATERIAL AND METHODS
Ethical aspects: The study was approved by the Ethics Committees
of Universidade Estadual de Londrina and of Universidade de São Paulo.
Patients were enrolled either at admission to the health care units or
during regular medical visits and were included after signing an
informed consent form.
Study population: A cross-sectional study was conducted as an
epidemiological investigation with descriptive and analytical
components. Serial blood samples were obtained by time, place and
conveniences. The population consisted of HIV-1-infected patients seen
at different Regional Health Units of the AIDS Reference Centers
(located in the cities of Londrina, Cornélio Procópio, Jacarezinho and
Ivaiporã, in Paraná State, South Brazil).
Serologic screening tests for HTLV-1/2:  Blood samples were
collected from September 2001 to December 2002 and were tested for
anti-HTLV-1/2 antibodies using two EIA kits with different antigens:
one consisting of purified viral lysates of HTLV-1 and HTLV-2,
associated with recombinant antigen p21E of HTLV-1 (VironostikaTM
HTLV-I/II, BioMeriéux, Bostel, The Netherlands), and the other
consisting of a synthetic peptide from the envelope protein of HTLV-1
and HTLV-2 associated with a recombinant transmembrane protein of
HTLV-2 (MurexTM HTLV-I+II, Abbott, Dartford Kent England, UK).
Reactive and discordant EIA samples were submitted to a confirmatory
WB (HTLV BLOT 2.4TM, Abbott Murex, Singapore System, Abbott,
Delkenhein, Germany). All assays were conducted and analyzed
according to manufacturer instructions.
Molecular biology approaches to confirm HTLV-1 and -2
infections: Patients who presented reactive or indetermined results on
WB assay were recalled for a new blood sampling. Peripheral
mononuclear blood cells (PBMC) were obtained by density gradient
centrifugation (HistopaqueTM - 1077, Sigma, St. Louis, USA) and stored
dry at -20 °C for DNA extraction and polymerase chain reaction (PCR).
Several genomic segments of HTLV-1 and HTLV-2 were amplified to
confirm HTLV-1 and HTLV-2 infection and to discard false-negative
or indeterminate results obtained by WB. Primers of the LTR, env and
tax regions of the genome were used as previously described, and
summarized in Table 17. In addition, to confirm the HTLV-2b subtype,
restriction fragment length polymorphism (RFLP) analyses were
performed using the PCR env products and the restriction enzyme XhoI,
of which the restriction site is present in HTLV-2a and 2c env sequences7-8,
and absent in HTLV-2b5.
Table 1
Set of primers used to amplify segments of the env, LTR and tax regions of the genomes of HTLV-1 and HTLV-2, nucleotides (nt) position, and size of the amplified
product in base pairs (bp)
Region Primer Sequence (5’                3’) Localization (nt) Product (bp)
HTLV-1
env D498 d ATG GGT AAG TTT CTG GCC 5202-5219a 1467
D500 d TTA CAG GGA TGA CTG AGG 6668-6651
TS1 d TTA TTC TTC CAG TTC TGC C 5229-5247 1421
TS2 d GTT TAT AAG AGA GTA ATG G 6649-6632
LTR LTR1 d AAT ATC CCC CGG GGG CTT AGA 22-42b 500
LTR3 d CAA GGG AGC GCC GGA CAA AG 521-502
LTR2 d CCA CGC TTT TAT AGA CTC CTG 337-317 316
tax/rex HTLV3 d GGA TAC CCC GTC TAC GTG TTT 7339-7359a 212
HTLV4 d GTG GTT CTC TGG GTG GGG AA 7550-7531
HTLV-2
env envA d ATG GGT AAT GTT TTC TTC 5180-5197c 1463
envB d TAT TAT AGC ATG GTT TCT 6642-6625
LUI7 d CCG TCT CCA GTC CAT CCT GGA 5547-5567 763
LUI8 d CCT CGT CTA TTT TGG GCT GCA 6309-6289
LTR VS1 d CAG GGC GAG TCA TCG ACC CAA AAG 35-58c 712
VS2 d GAA GAC AAT GCT CCT AGG GCG GGC 746-724
VS3 d ACC GTC TCA CAC AAA CAA TCC C 64-85 666
VS4 d GCG GGC CTG CCT ATA GCG ATG 729-709
tax tax 3 d CGG CCT TTT GCT GTC CTT 7077-7094d 1254
tax 4 d GTC AGG GCC TTG GTT TCA 8330-8313
tax 5 d GCA CCA GCT CAC CT 7364-7377 967
a
 relative to ATK isolate of HTLV-1, accession number J02029; b relative to HS35 isolate of HTLV-1, accession number D13784; c relative to
MoT isolate of HTLV-2, accession number M10060; d relative to NRA isolate of HTLV-2, accession number L20734.
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Table 2
Results obtained by screening and confirmatory tests for HTLV-1 and HTLV-2 infections, and HTLV-2 subtyping among 49 HIV/AIDS
patients from Londrina and region
Pt n. Viral lysate EIA Recombinant EIA WB pattern PCR RFLP
VironostikaTM MurexTM HTLV 2.4TM env HTLV-2
Result OD/CO Result OD/CO
1 + 1.3 - 0.3 - -
2 + 1.9 + >9.0 Ind. (GD21,rgp46-II) + 2a/c
3 + 1.4 + >9.0 Ind. (GD21,rgp46-II) + 2a/c
4 + 1.4 + >9.0 Ind. (GD21) + 2a/c
5 - 0.8 + 7.7 Ind. (GD21) + 2a/c
6 - 0.6 + >9.0 Ind. (GD21,rgp46-II) + 2a/c
7 + 1.4 + >9.0 HTLV-2 + 2a/c
8 + 2.6 + >9.0 Ind. (GD21,p24) + 2a/c
9 + 1.9 + >9.0 HTLV-2 + 2a/c
10 + 1.2 + >9.0 HTLV-2 + 2a/c
11 + 1.7 + >9.0 HTLV-2 + 2a/c
12 + 4.3 + >9.0 HTLV-2 + 2a/c
13 + 3.1 + >9.0 HTLV-2 + 2a/c
14 + 3.4 + >9.0 HTLV-1 + ND
15 + 3.9 + >9.0 HTLV-1 + ND
16 + 1.5 + >9.0 Ind. (GD21) + 2a/c
17 + 1.4 + >9.0 - - ND
18 - 0.8 + 8.4 Ind. (GD21,rgp46-II) + 2a/c
19 + 1.0 + 8.9 Ind. (GD21,rgp46-II) + 2a/c
20 - 0.9 + 2.2 - - ND
21 + 1.7 + >9.0 Ind. (GD21,p24) + 2a/c
22 + 1.4 + >9.0 Ind. (GD21,p24) + 2a/c
23 + 1.8 + >9.0 HTLV-2 + 2a/c
24 + 1.8 + >9.0 HTLV-2 + 2a/c
25 + 1.7 + >9.0 HTLV-2 + 2a/c
26 + 2.5 + >9.0 HTLV-2 + 2a/c
27 + 2.4 + >9.0 HTLV-2 + 2a/c
28 + 3.4 + >9.0 HTLV-2 + 2a/c
29 + 2.1 + >9.0 HTLV-2 + 2a/c
30 + 2.2 + >9.0 HTLV-1 + ND
31 + 3.6 + 3.1 - ND ND
32 - 0.9 + 7.0 Ind. (GD21,p24) + 2a/c
33 + 1.1 + 9.0 Ind. (GD21,p24) ND ND
34 + 2.4 + >9.0 Ind. (GD21,p24) - ND
35 + 1.2 + 9.0 Ind. (rgp46-II) + 2a/c
36 + 1.2 + >9.0 HTLV-2 + 2a/c
37 + 4.1 + >9.0 HTLV-2 + 2a/c
38 + 1.6 + >9.0 HTLV-2 + 2a/c
39 + 1.8 + >9.0 HTLV-2 + 2a/c
40 + 3.0 + >9.0 HTLV-2 + 2a/c
41 + 3.7 + >9.0 HTLV-2 + 2a/c
42 + 3.8 + >9.0 HTLV-2 + 2a/c
43 + 3.6 + >9.0 HTLV-1 + ND
44 + 3.7 + >9.0 HTLV-1 + 2a/c
45 + 3.1 + >9.0 HTLV-1 + ND
46 + 1.1 + >9.0 HTLV-1 + ND
47 + 1.3 + >9.0 Ind. (GD21,p24) + 2b
48 + 3.1 + >9.0 HTLV-2 + 2a/c
49 + 1.3 + >9.0 HTLV + 2a/c
HTLV-1 - Human T-lymphotropic virus type 1; HTLV-2 - Human T-lymphotropic virus type 2; HIV/aids - Human immunodeficiency virus/acquired immunodeficiency
syndrome; HTLV-1/2 - Human T-lymphotropic virus type 1 and 2; HTLV - Human T-lymphotropic virus not typing; Pt n. - Patient number; EIA - Enzyme-linked
immunosorbent assay; WB - Western Blotting; OD/CO - optic density/cut-off; Ind - Indeterminate; (-) - negative; (+) - positive; PCR - Polymerase chain reaction; RFLP
- Restriction fragment length polymorphism; ND - Not done.
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RESULTS
From September 2001 to December 2002, 784 HIV-1-infected
patients were attended at the AIDS Reference Centers in Londrina and
region where their blood samples were collected. Twenty-six (3.3%)
of 784 patients did not allow blood collection and were excluded from
the study. Among 758 serum samples analyzed for the presence of
HTLV-1/2 antibodies by the EIA viral lysate kit and EIA recombinant
kit, 709 (93.5%) resulted non-reactive and 49 (6.5%) were reactive in
at least one of the kits.
Forty-three sera (87.8%) presented concordant results with EIA
tests; out of these, two (4.7%) were WB negative, seven (16.3%)
confirmed infection by HTLV-1, 21 (48.8%) by HTLV-2, one (2.3%)
by HTLV. It was not possible to confirm infection by HTLV in 12
cases (27.9%), evidencing an indeterminate WB pattern (Table 2).
Six serum samples (12.2%) resulted discordant in the screening
EIA tests, and when analyzed by WB, two (33.3%) were considered
negative and four (66.7%) HTLV indeterminate (Table 2).
For the 49 reactive or discordant samples in the serologic screening,
it was possible to perform PCR in 47 cases (95.9%), of which four
(8.5%) resulted negative and 43 (91.5%) confirmed the presence of
DNA/HTLV in the PBMC for the three different regions of the genome.
Of these, 37 (86%) were HTLV-2 positive and six (14%) were HTLV-
1 positive. One sample (pt. 44) showed discordant results: HTLV-1
seroreactivity and HTLV-2 truly infection by PCR analysis. This patient
was then referred to a new blood collection and the results confirmed
previous information (Table 2).
Using WB as the “gold standard” to define HTLV-1 and -2
infections, the results demonstrated that both EIA kits were highly
sensitive in detecting HTLV-1 and HTLV-2 antibodies (Table 3). On
the other hand, in using PCR as the “gold standard”, the ELISA
recombinant test was more sensitive than the viral lysate EIA for
detecting HTLV-2-specific antibodies (100.0% vs 89% sensitivity,
respectively) (Table 4). When a 20.0% reduced cut-off value was used
for the viral lysate assay, the sensitivity of HTLV-2 antibody detection
was increased; however, one case that was classified as HTLV-2 positive
by PCR remained negative with the reduced cut-off (pt. 6, Table 2).
The 37 PCR positive samples for HTLV-2 had their env PCR
products tested by the RFLP technique in order to rapidly search for
HTLV-2b subtype. One out of 37 amplicons did not present the
restriction site for enzyme XhoI and was subtyped as HTLV-2b, while
36 (97.3%) presented this site and were subtyped as HTLV-2a/c.
DISCUSSION
The municipality of Londrina ranks second in the number of AIDS
cases in the Paraná State, Brazil, and almost the totality of HIV/AIDS
patients attended at the AIDS Reference Centers in Londrina and region
during the years of 2001-2002 had their blood collected and analyzed
previously for the seroprevalence and risk factors for HTLV-1 and -2,
as well as hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis.
The results obtained disclosed an overall seroprevalence of 6.4% for
HTLV-1/2; 0.8% for HTLV-1 and 4.9% for HTLV-2, and a strong
association with IDU24. On the other hand, Brazil is a country which
possess HTLV-2 endemic and epidemic populations, but the majority
of epidemiological and molecular studies referred data on the North
Table 3
Comparison of the HTLV-1/2 serological results obtained in a population of 758 HIV-1-infected individuals using the Western Blot test as the gold standard
Western Blot n Viral lysate Sensitivity Recombinant Sensitivity
EIA-VironostikaTM (%) EIA - MurexTM (%)
HTLV-1 Positive 7 7 100 7 100
HTLV-2 Positive 21 21 100 21 100
HTLV Positive 1 1 100 1 100
Indeterminate 16 12 75 16 100
Negative 4 3 75 3 75
HIV-1 - Human immunodeficiency virus type 1; n - population; EIA - Enzyme immunoassay; HTLV-1 - Human T-lymphotropic virus type 1; HTLV-2 - Human
T-lymphotropic virus type 2; HTLV - Human T-lymphotropic virus not typing.
Table 4
Comparison of the HTLV-1/2 serological results obtained in a population of 758 HIV-1 infected individuals using PCR assay as the gold standard
PCR n Viral lysate Sensitivity Recombinant Sensitivity
EIA-VironostikaTM (%) EIA - MurexTM (%)
HTLV-1 Positive 6 6 100 6 100
HTLV-2 Positive 37 33 89 37 100
Negative 4 3 75 3 75
HIV-1 - Human immunodeficiency virus type 1;  n - population; EIA - Enzyme immunoassay; HTLV-1 - Human T-lymphotropic virus type 1; HTLV-2 - Human
T- lymphotropic virus type.
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and Southeast regions of Brazil28. Only very recently, a study conducted
in Porto Alegre, South of Brazil, disclosed the presence of both, HTLV-
2a and HTLV-2b among urban individuals from this geographic area.
Thus, in order to add some information concerning HTLV-1 and -2
infections in the South of Brazil, we conducted the present study.
The same cohort of HIV/AIDS patients from Londrina and region
early evaluated for HTLV-1/2 seroprevalence24, were now confirmed
HTLV-1 and -2 infected by molecular approaches, and careful analysis
of serologic screening tests was performed in order to establish the
ideal testing algorithm useful in Brazil.
The serological analysis disclosed both EIAs as 100% sensitive in
detecting HTLV-1 infection, the same sensitivity previously described
for HTLV-1 infection in Japan14.  In contrast, for HTLV-2 truly infection,
the viral lysate EIA kit detected only 89% of cases, while the
recombinant EIA, 100% of cases. These results are in accordance with
the results obtained by others2,26.
The strategy of using two, instead of one, EIA screening test for
HTLV-2 serology, increased the sensitivity in detecting HTLV-2 from
89.9% to 97.5%31.  Indeed, the EIAs which have recombinant proteins
and/or synthetic peptides of HTLV-1 and of HTLV-2 and that use the
“sandwich” principle, are highly sensitive and specific in detecting
HTLV antibodies when compared with indirect assays that use only
viral lysates2,33. Here, the recombinant test (“sandwich”) showed the
best performance in detecting HTLV-2-infected patients, including
patients whose sera resulted indeterminate on WB.
Of note, the indeterminate WB profile observed in the present study
differs from the HTLV-1 gag indeterminate profile (HGIP) described
in Africa, associated with P. falciparum infection23. Here, the majority
of sera presented reactivity to GD21 and/or gp46-II, p24, and could
reflect HTLV-2 seroconversion. Delayed HTLV-1 seroconversion in
sero-indeterminate blood donors from endemic regions were early
detected11.
Previous studies showed that WB has a sensitivity ranging from
70% to 84% in detecting HTLV-2 infection26,31, and the PCR’s sensitivity
of 85.1%20. Thus, both tests lack in detecting all HTLV-2-infected cases,
requiring an association of the WB and PCR assays26.
The Centers for Disease Control (CDC) using a questionnaire sent
to several laboratories in the United States showed that only 18.5% of
the laboratories performed the WB test, and 8.8% used other methods
including PCR, antigen detection, radioimmunoprecipitation assay
(RIPA), and viral culture10. At Brazilian blood centers, the serologic
screening of HTLV-1/2 infection with two EIAs of different principles
seems to be enough to discard donation bags. On the other hand, whether
the purpose is to diagnose HTLV-2 infection in high-risk population,
the recombinant EIA and PCR assays seems to be the best choice.
An interesting event detected in the present study was the discordant
results obtained by WB and PCR in one patient; he was considered
HTLV-1-infected by the WB test, and HTLV-2-infected by the PCR of
the env, LTR and tax regions of the virus genome. A second blood
collection and analyses of this patient supported the results previously
obtained. Thus, we could hyphotesize that antibodies against gp46 of
the HTLV-2 strain that infect this patient cross-react with the rgp46-I
present on the WB strip.  Similar discordant results were described in
other infected patients from Brazil6,9.
The sole HTLV-2b case detected in the present study contrast with
the large number of cases detected in Porto Alegre27. Nevertheless, we
have to consider the risk factors and HIV status of the populations
analyzed, which could influence on the results obtained. Interestingly,
the HTLV-2b-infected patient from Londrina was of a Paraguayan
origin.
In conclusion, the data presented in this study suggest the use of
recombinant EIA as screening, and PCR as confirmatory tests in HTLV-
2 diagnosis of high-risk population of Brazil, and confirm the presence
of HTLV-2b in the South of this country.
RESUMO
Dificuldades no diagnóstico de infecção por HTLV-2 em
pacientes com HIV/AIDS do Brasil: análise comparativa de
ensaios sorológicos e moleculares e detecção de subtipo HTLV-2b
O diagnóstico de infecção por HTLV-2 se baseia na pesquisa de
anticorpos específicos, entretanto, vários estudos conduzidos no Brasil
têm apontado falhas nos kits sorológicos disponíveis no mercado em
detectar HTLV-2, principalmente nos pacientes com HIV/aids. Este
trabalho avaliou a presença de infecção por HTLV-1 e -2 em 758
pacientes HIV/aids de Londrina, Paraná, Brasil. Amostras de soro foram
analisadas quanto à presença de anticorpos anti-HTLV-1/2 por dois
kits de EIA (Vironostika e Murex) e confirmados por WB (HTLV Blot
2.4, Genelabs). Os resultados obtidos pelos testes sorológicos
mostraram 49 (6,5%) soros reagentes: 43 positivos para ambos os kits
e seis com resultados discordantes. O WB confirmou infecção por
HTLV-1 em sete soros (0,9%) e HTLV-2 em 21 soros (2,8%). Resultados
negativos e indeterminados foram detectados, respectivamente, em
quatro (0,5%) e 16 (2,1%) soros. Amostras de sangue de 47 dos 49
pacientes com sorologia reagente foram avaliadas quanto à presença
de segmentos do genoma dos HTLVs (env, LTR e tax), usando a técnica
de PCR. As PCRs confirmaram seis casos de infecção por HTLV-1 e
37 casos por HTLV-2 (14 dos 16 cuja sorologia resultou WB
indeterminada). A subtipagem de HTLV-2 por análise de restrição
enzimática de produtos da PCR env mostrou 36 isolados de subtipo
HTLV-2a/c e um HTLV-2b. Esses resultados reforçam a necessidade
de melhorar o diagnóstico de infecção por HTLV-2 no Brasil e
confirmam a presença do subtipo HTLV-2b na região sul do país.
REFERENCES
1. ALCANTARA, L.C.J.; SHINDO, N.; VAN DOREN, S. et al. - Brazilian HTLV type 2a
strains from intravenous drug users (IDUs) appear to have originated from two
sources: Brazilian Amerindians and European/North American IDUs. AIDS Res.
hum. Retrovir., 19: 519-523, 2003.
2. ANDERSSON, S.; THORSTENSSON, R.; RAMIREZ, K.G. et al. - Comparative
evaluation of 14 immunoassays for detection of antibodies to the human T-
lymphotropic virus types I and II using panels of sera from Sweden and West Africa.
Transfusion, 39: 845-851, 1999.
3. ARAUJO, A. & HALL, W.W. - Human T-lymphotropic virus type II and neurological
disease. Ann. Neurol., 56: 10-19, 2004.
230
MORIMOTO, H.K.; MORIMOTO, A.A.; REICHE, E.M.V.; UEDA, L.T.; MATSUO, T.; REICHE, F.V. & CATERINO-DE-ARAUJO, A. - Difficulties in the diagnosis of HTLV-2 infection in
HIV/AIDS patients from Brazil: comparative performances of serologic and molecular assays, and detection of HTLV-2b subtype. Rev. Inst. Med. trop. S. Paulo, 49(4):225-230, 2007.
4. ARAUJO, A.; SHEEHY, N.; TAKAHASHI, H. et al. - Concomitant infections with human
immunodeficiency virus type 1 and human T-lymphotropic virus types 1 and 2. In:
BROGDEN, K.A. & GUTHMILLER, J.M., ed. Polymicrobial diseases. Washington,
ASM, 2002. p. 75-97.
5. CALABRÒ, M.L.; LUPARELLO, M.; GROTTOLA, A. et al. - Detection of human T-
lymphotropic virus type II/b in human immunodeficiency virus type 1-coinfected
persons in southeastern Italy. J. infect. Dis., 168: 1273-1277, 1993.
6. CASSEB, J.; CATERINO-DE-ARAUJO, A.; HONG, M.A. et al. - Prevalence of HTLV-
I and HTLV-II infections among HIV-1-infected asymptomatic individuals in São
Paulo, Brazil. Rev. Inst. Med. trop. S. Paulo, 39: 213-215, 1997.
7. CATERINO-DE-ARAUJO, A.; FAVERO, A.; SANTOS-FORTUNA, E. et al. - HTLV-I/
HTLV-II coinfection in an AIDS patient from São Paulo, Brazil. AIDS Res. hum.
Retrovir., 16: 715-719, 2000.
8. CATERINO-DE-ARAUJO, A.; FAVERO, A.; SANTOS-FORTUNA, E. et al. - Molecular
characterization of HTLV strains from HIV-1-infected intravenous drug users from
São Paulo, Brazil. In: INTERNATIONAL CONFERENCE ON HUMAN
RETROVIROLOGY: HTLV,  8., Rio de Janeiro, 1997. p. ME08.
9. CATERINO-DE-ARAUJO, A.; SANTOS-FORTUNA, E.; MELEIRO, M.C.Z. et al. -
Sensitivity of two enzyme-linked immunosorbent assay tests in relation of Western
Blot in detecting human T-cell lymphotropic virus types I and II infection among
HIV-1 infected patients from São Paulo, Brazil. Diagn. Microbiol. infect. Dis., 30:
173-182, 1998.
10. CDC. Centers for Disease Control and Prevention - Results of the 1999 retroviral testing
survey questionnary sent to laboratories participating in the model performance
evaluation program, 1999, July 15, 2001. Available at: http://www.phppo.cdc.gov/
mpip/pdf/rq9903.
11. CÉSAIRE, R.; BERA, O.; MAIER, H. et al. - Seroindeterminate patterns and
seroconversions to human T-lymphotropic virus type I positivity in blood donors
from Martinique, French West Indies. Transfusion, 39: 1145-1149, 1999.
12. COVAS, D.T. & KASHIMA, S. - Complete nucleotide sequences of the genomes of two
Brazilian specimens of human T lymphotropic virus type 2 (HTLV-2). AIDS Res.
hum. Retrovir., 19: 689-697, 2003.
13. EIRAKU, N.; NOVOA, P.; DA COSTA FERREIRA, M. et al. - Identification and
characterization of a new and distinct molecular subtype of human T-cell
lymphotropic virus type 2. J. Virol., 70: 1481-1492, 1996.
14. FUJIYAMA, C.; FUJIYOSHI, T.; MATSUMOTO, D.; TAMASHIRO, H. & SONODA,
S. - Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel.
Bull. Wld Hlth Org., 73: 515-521, 1995.
15. ISHAK, R.; HARRINGTON Jr., W.J.; AZEVEDO, V.N. et al. - Identification of human
T cell lymphotropic virus type IIa infection in the Kayapo, an indigenous population
of Brazil. AIDS Res. hum. Retrovir., 11: 813-821, 1995.
16. ISHAK, R.; VALLINOTO, A.C.R.; AZEVEDO, V.N. & ISHAK, M.Q. - Epidemiological
aspects of retrovirus (HTLV) infection among Indian populations in the Amazon
Region of Brazil. Cadern. Saúde públ. (Rio de J.), 19: 109-114, 2003.
17. LAL, R.B.; PARDI, D.; SWITZER, W.; SEGURADO, A. & BLACK, F. - Immune
reactivity of HTLV-IIa-infected Kayapo Indians with HTLV-IIb extended tax epitope.
J. acquir. immune Defic. Syndr. hum. Retrovir., 14: 476-477, 1997.
18. LAURENTINO, R.V.; LOPES, I.G.L.; AZEVEDO, V.N. et al. - Molecular characterization
of human T-cell lymphotropic virus coinfecting human immunodeficiency virus 1
infected patients in the Amazon region of Brazil. Mem. Inst. Oswaldo Cruz, 100:
371-376, 2005.
19. LEWIS, M.J.; NOVOA, P.; ISHAK, R. et al. - Isolation, cloning, and complete nucleotide
sequence of a phenotypically distinct Brazilian isolate of human T-lymphotropic
virus type II (HTLV-II). Virology, 271: 142-154, 2000.
20. LIU, H.; SHAH, M.; STRAMER, S.L. et al. - Sensitivity and specificity of human T-
lymphotropic virus (HTLV) types I and II polymerase chain reaction and several
serologic assays in screening a population with a high prevalence of HTLV-II.
Transfusion, 39: 1185-1193, 1999.
21. MACEDO, O.; RIBEIRO-LIMA, T.V.; LINHARES, A.O. et al. - Human T-cell
lymphotropic virus types I and II infections in a cohort of patients with neurological
disorders in Belém, Pará, Brazil. Rev. Inst. Med. trop. S. Paulo, 46: 13-17, 2004.
22. MACHUCA, A. & SORIANO, V. - In vivo fluctuation of HTLV-I and HTLV-II proviral
load in patients receiving antiretroviral drugs. J. acquir. immune Defic. Syndr., 24:
189-193, 2000.
23. MAHIEUX, R.; HORAL, P.; MAUCLÈRE, P. et al. - Human T-cell lymphotropic virus
type 1 gag indeterminate Western blot patterns in Central Africa: relationship to
Plasmosium falciparum infection. J. clin. Microbiol., 38: 4049-4057, 2000.
24. MORIMOTO, H.K.; CATERINO-DE-ARAUJO, A.; MORIMOTO, A.A. et al. -
Seroprevalence and risk factors for human T cell lymphotropic virus type 1 and 2
infection in human immunodeficiency virus-infected patients attending AIDS Referral
Center Health Units in Londrina and other communities in Paraná, Brazil. AIDS
Res. hum. Retrovir., 21: 256-262, 2005.
25. MURPHY, E.L.; GRANT, R.M.; KROPP, J. et al. - Increased human T-lymphotropic
virus type II proviral load following highly active retroviral therapy in HIV-coinfected
patients. J. acquir. immune Defic. Syndr., 33: 655-656, 2003.
26. POIESZ, B.J.; DUBE, S.; CHOI, D. et al. - Comparative performances of an HTLV-I/II
EIA and other serologic and PCR assays on sample from persons at risk for HTLV-
II infection. Transfusion, 40: 924-930, 2000.
27. RENNER, J.D.P.; LAURINO, J.P.; MENNA-BARRETO, M. & SCHMITT, V.M. -
Molecular evidence of HTLV-II subtype b among urban population living in South
Brazil. AIDS Res. hum. Retrovir., 22: 301-306, 2006.
28. ROUCOUX, D.F. & MURPHY, E.L. - The epidemiology and disease outcomes of human
T-lymphotropic virus type II. AIDS Rev., 6: 144-154, 2004.
29. SALEMI, M.; LEWIS, M.; EGAN, J.F. et al. - Different population dynamics of human
T cell lymphotropic virus type II in intravenous drug users compared with endemically
infected tribes. Proc. nat. Acad. Sci. (Wash.), 96: 13253-13258, 1999.
30. SHINDO, N.; ALCANTARA, L.C.J.; VAN DOOREN, S. et al. - Human retroviruses
(HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular
epidemiology of HTLV type 2 isolates. Aids Res. hum. Retrovir., 18: 71-77, 2002.
31. THORSTENSSON, R.; ALBERT, J. & ANDERSSON, S. - Strategies for diagnosis of
HTLV-I and II. Transfusion, 42: 780-791, 2002.
32. VANDAMME, A.M.; SALEMI, M.; VAN BRUSSEL, M. et al. - African origin of human
T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d
subtype in Congolese Bambuti Efe Pygmies. J. Virol., 72: 4327-4340, 1998.
33. VRIELINK, H.; REESINK, H.W.; HABIBUW, M. et al. - Comparison of four HTLV-I
and HTLV-I + II ELISAs. Vox Sang. (Basel), 76: 187-191, 1999.
Received: 25 July 2006
Accepted: 28 November 2006
